MBX Capital

MBX Capital is a venture capital firm dedicated to investing in "deep health" companies, focusing on startups that address the root causes of environmental health and healthcare infrastructure challenges. The firm targets innovative startups that leverage advancements in biology, chemistry, artificial intelligence (AI), machine learning (ML), robotics, and clinical medicine to develop advanced solutions. Their overarching mission is to improve human health through groundbreaking innovations, which includes initiatives aimed at environmental cleanup, the replacement of hazardous chemicals, and the development of novel medicines and diagnostics.

Founded in 2015, MBX Capital was established by co-founders Gurdane Bhutani and Zeshan Muhammedi. The firm's inception was driven by the critical insight that addressing the fundamental causes of illness and promoting environmental health are paramount. This foundational principle guides their investment strategy, supporting visionary entrepreneurs who are developing sustainable environmental solutions, novel medicines, and advanced diagnostics.

MBX Capital's diverse portfolio includes companies such as Tidal Vision, which focuses on pollution abatement in water and agriculture; Junction Health, providing infusion therapy infrastructure for community health centers; and Examol, developing cloud infrastructure for computational chemistry. Other notable investments include Vivodyne (organoids-on-a-chip), SecureAire (indoor air pollution), ixLayer (precision health testing), Attivare Tx (biomaterial vaccine platform), Path CCM (mental healthcare), and Macro Trials (clinical trials). The firm also supports companies like Keebler Health, Think Bioscience, Persist AI, Contraline, Luna, Concert Health, Koneksa Health, Atlas Labs, and Buoy Health. MBX Capital typically invests in early-stage rounds, including Pre-Seed, Seed, Series A, and Series B.

The firm is led by its co-founders, Gurdane Bhutani and Zeshan Muhammedi, who bring extensive expertise to their roles as Managing Partners. A key differentiator for MBX Capital is its "Atom Network," a private community of over 1700 venture partners comprising physicians, scientists, and industry executives. These network members contribute capital, time, and specialized expertise, providing hands-on support and strategic guidance to MBX Capital's portfolio companies. The firm employs a scientific approach to investing, utilizing this distributed network of experts for rigorous peer-review of prospective startups and leveraging a dedicated engineering organization for advanced analytics and investment screening.